



INVITROCUE

FACT SHEET
JULY 2016

INVITROCUE LIMITED (ASX:IVQ)

HEALTHCARE AND LIFE SCIENCES SERVICES AND PRODUCTS


InvitroCue is a life sciences company that provides bioanalytics solutions for the pharmaceutical and medical industries.

The company conducts fee-for-service laboratory testing of new drugs, vaccines, therapeutics and cosmetics for biopharmaceutical clients. It also earns revenues from its digital pathology business, which scans and digitises physical tissue slides for pathologists around the world to access via an online portal, and analyses the slides via its proprietary image analysis softwares and algorithms.


In May 2016, InvitroCue entered the oncology drug testing market in selected solid tumours. Through its revolutionary 3D cell-based scaffolding technology and proprietary processes, the company can culture patient-derived cancer cells in its laboratories for testing against a panel of approved drugs and new drug candidates.

This Onco-PDO (patient-derived organoid) business enables pharmaceutical companies, medical researchers and academic institutions to understand the impact of cancer treatments prior to conducting time consuming and expensive clinical trials. Onco-PDO also paves the way for a new market in assessing the effects of FDA-approved drugs on individuals before they are administered (see infographic*).

The company's technology was spun out of A*STAR (Singapore's equivalent of CSIRO) and developed in partnership with MIT and the University of Singapore. It has been validated in collaboration with leading biopharmaceutical clients and scientific collaborators.



Onco-PDO ANALYTICS TESTING



INVESTMENT HIGHLIGHTS

1. First mover advantage in patented and proven technology '3D cell-based scaffolding'
2. Highly scalable business model: versatile and powerful platform technology with wide applicability and low-cost of implementation
3. Affordable price point for personalised Onco-PDO; oncologists to drive and adopt technology for calculating patient's benefit.
4. Research collaboration with Suzhou University hospital (China) to conduct personalised testing for non-small lung cell cancer; initial data is expected to be published in Q4 2016
5. Exploring collaborations with other renowned hospitals and academic institutions for other cancers and malignancies: colorectal, breast and prostate
6. High profile management team (led by Dr Steven Fang) and Scientific Advisory Board (led by international Key Opinion Leaders)

PATIENT-DERIVED ORGANOID IN PERSONALISED DRUG TESTING

1. GLOBAL CANCER MARKETS

The World Health Organization estimates that the incidence of cancer could increase from 14.1 million new cases in 2012 to about 22 million by 2030¹. This represents an increase of 60% overall, with rates nearly doubling in some developing countries in Asia.

Source:

World Health Organization's International Agency for Research on Cancer, GLOBOCAN 2012: Estimated Cancer Incidence, Mortality and Prevalence Worldwide in 2012.

2. POLICY-DRIVEN IMPACT THROUGH 2016

During January 2016 of Union Address, President Obama had announced a new USD 1 Billion (Cancer Moonshot Initiative) to jumpstart and accelerate research efforts and collaborations with researchers, doctors, philanthropies, patients, and patient advocates and biotechnology and pharmaceutical companies to identify new ways to prevent, diagnose and treat cancer.

Source:

Fact Sheet: Investing in the National Cancer Moonshot", National Cancer Institute.

Following the U.S., China is set to announce a series of policies and measures centered around the concept of prevention, diagnosis and treatment strategies that take individual variability into consideration; this initiative is recognized as country's key science and technology projects under China's 13th Five-Year Plan (2016-2020).

Source: China Daily: http://www.chinadaily.com.cn/china/2015ccplenarysession/2015-11/09/content_22406135.htm

3. TECHNOLOGY AND PERSONALISED MEDICINE TESTING

Using its revolutionary 3D cell-based technology and proprietary processes, InvitroCue will be able to culture patient derived tumour cells (an organoid) in its laboratories for testing against a panel of approved drugs. The company will be among the first to offer such tests in Asia.

Source: <http://www.asx.com.au/asxpdf/20160512/pdf/4376773wkfv5nm.pdf>

COMPANY DATA

Share Price:

AUD \$0.085 (as at 08 June 2016)

Issued Capital:

444,089,053

Market Cap:

AUD \$3,747,570 (as at 08 June 2016)

Low-High:

AUD \$0.060 – \$0.110

Cash:

AUD \$2,075,568 (as at 31 March 2016)

Debt: AUD \$0

SCIENTIFIC ADVISORY BOARD

Professor Alex MATTER

MD (Singapore)

Professor Joseph King-Tak LEE

MD FACR (USA)

Professor Simon CROFT

BSC PGCE PHD FRSB (UK)

Professor Shervanthi HOMER-VANNIASINKAM

BSC MBBS MD FRCSEd FRCS (UK)

Associate Professor Soo Yong TAN

MBBS FRCPath DMJ DPhil (Singapore)

MAJOR SHAREHOLDERS

(UPDATED 14 JAN 2016)

Steven Fang – 26.06%

Faith Champ Enterprise Ltd – 18.58%

Henry Yu – 11.17%

Clearbridge Accelerator Pte Ltd – 8.57%

Chan Yat Kei – 4.64%

LEADERSHIP TEAM

Dr Steven FANG (PhD MBA)

Executive Director

Professor Henry YU (PhD)

Non-Executive Director, Scientific Mentor and Advisor

Martin Bach

Vice President, Operations

AUSTRALIA CORPORATE OFFICE

InvitroCue Limited

Level 13135, King Street Sydney, NSW 2000 Australia

SINGAPORE CORPORATE OFFICE

InvitroCue Pte Ltd

11 Biopolis Way, Helios #12 – 07/08, Singapore 138667

CHINA CORPORATE OFFICE

InvitroCue Biomedical Service Suzhou

Room 336, Block 2 Public Academy, No. 377 Linquan Street, Suzhou Industrial Park, Jiangsu China 215123

CHINA JOINT LAB

No. 398 Ruoshui Road, Chinese Academy of Sciences, Suzhou Industrial Park, Jiangsu China 215123

SINGAPORE TOXICOLOGY LAB

Block 4, Unit IT4-3-91, School of Applied Science, Temasek Polytechnic, 21 Tampines Avenue 1, Singapore 529757

Investor Contact:

Matthew Gregorowski

Citadel-MAGNUS

Tel: +61 2 8234 0100

Email: mgregorowski@citadelmagnus.com